Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
J Med Chem. 2022 Jan 27;65(2):935-954. doi: 10.1021/acs.jmedchem.1c00302. Epub 2021 May 10.
Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potential solution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylation events that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost and effectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistry programs are needed in the field. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering the role of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viral infections in different development stages.
病毒感染是一个主要的健康问题；因此，我们迫切需要新的治疗策略。用于针对病毒基因组编码的蛋白质的抗病毒药物通常会增强病毒产生的耐药性。一种潜在的解决方案可能是针对宿主靶点的药物，因为病毒依赖于许多细胞蛋白和磷酸化事件，这些事件在其生命周期中至关重要。将现有的激酶抑制剂重新用于抗病毒药物的研发有助于降低成本和提高效果，但这种策略通常并不能带来很大的改善，因此在该领域需要特定的药物化学方案。无论如何，广泛使用 FDA 批准的激酶抑制剂在解析宿主激酶在病毒感染中的作用方面非常有用。本综述旨在回顾针对不同发展阶段的病毒感染的激酶抑制剂的最新研究进展。
